Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
Medicare Part D
[By Staff Writers]
The CMS reported in USA Today that Medicare beneficiaries are likely to see a smaller number of drugs covered under Part D plans next year, as insurers revise offerings and the government reduces hundreds of products from a list of approved drugs.
On average, the number of drugs offered by the 10 insurers with the largest enrollment shrank by 26 percent from this year to next. Two of the largest insurers – UnitedHealth and Humana – saw drops of 30 percent in some of their plans, from more than 3,750 drugs to just more than 2,620. The drop came mainly because of changes made by Medicare, which shrank the list of drugs it will pay for – reducing those that have been pulled by the FDA, are no longer being made, had duplicative billing codes or were drugs deemed “less than effective”.
Medicare officials and insurers opine that most beneficiaries are unlikely to be affected, and that enrollees taking drugs that were pulled will usually be able to find alternates, or can go through an appeals process to try to stay on their current drugs.
And so, do “fewer covered drugs” help or hurt Medicare D recipients?
Conclusion
Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.
Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com
OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:
LEXICONS: http://www.springerpub.com/Search/marcinko
PHYSICIANS: www.MedicalBusinessAdvisors.com
PRACTICES: www.BusinessofMedicalPractice.com
HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
CLINICS: http://www.crcpress.com/product/isbn/9781439879900
ADVISORS: www.CertifiedMedicalPlanner.org
BLOG: www.MedicalExecutivePost.com
Share this:
Filed under: Drugs and Pharma | Tagged: Big Pharma and Drugs | 1 Comment »
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 